KA
ABEO icon

Kovack Advisors’s Abeona Therapeutics ABEO Stock Holding History

Kovack Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.4K Buy
+10,560
New +$52.8K ﹤0.01% 995

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Kovack Advisors's ABEO Position: Q1 2026 in Review

Kovack Advisors opened a new position in Abeona Therapeutics (ABEO) in Q1 2026: 10,560 shares worth $48.4K. The stake represents ﹤0.01% of the portfolio and ranks #995 among its holdings.

108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Kovack Advisors held 10,560 shares of Abeona Therapeutics worth $48.4K as of Q1 2026.
  • Abeona Therapeutics was a new Kovack Advisors position in Q1 2026.
  • Abeona Therapeutics made up ﹤0.01% of Kovack Advisors's portfolio in Q1 2026, its #995 holding.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Kovack Advisors's 13F filing for Q1 2026, filed 13 May 2026.